Dr. Reddy’s Q3 & 9M FY21 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Dr. Reddys Labs (RDY) Reports Q3 EPS of $0.02
January 29, 2021 5:49 AM ESTDr. Reddys Labs (NYSE: RDY) reported Q3 EPS of $0.02, versus ($0.47) reported last year. Revenue for the quarter came in at $675 million, versus $600 million reported last year.
Commenting on the results, Co-chairman & MD, G V Prasad said, We continued with our growth momentum while... More
